Enterprise Value
272.1M
Cash
2.034M
Avg Qtr Burn
-4.633M
Short % of Float
0.00%
Insider Ownership
6.01%
Institutional Own.
0.06%
Qtr Updated
02/28/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Leronlimab (PRO 140) Details Human immunodeficiency virus | BLA FDA meeting | |
Leronlimab Details Non-alcoholic steatohepatitis | Phase 2/3 Initiation | |
Leronlimab Details Solid tumor/s, Cancer | Phase 2 Update | |
Leronlimab Details Graft-versus-host disease | Failed Discontinued | |
Leronlimab (PRO 140) Details COVID-19 | Failed Discontinued |